title: Intravitreal Bevacizumab for Traumatic Choroidal Rupture.
abstract: OBJECTIVE
  To report a case of visual loss associated with traumatic choroidal rupture after blunt ocular trauma that was successfully treated with an early intravitreal bevacizumab injection despite the absence of choroidal neovascularization (CNV).
  
  
  METHODS
  A 14-year-old boy presented with visual disturbance in his left eye after sustaining an ocular contusion 4 weeks earlier. The best-corrected visual acuity (BCVA) in the left eye was 20/50. Funduscopic examination revealed macular choroidal rupture accompanied by subretinal hemorrhage. Optical coherence tomography (OCT) showed accumulation of subretinal fluid around a disrupted retinal pigment epithelium/Bruch membrane complex extending into the juxtafoveolar area, but there was no active leakage suggestive of CNV on fluorescein angiography. Intravitreal bevacizumab (1.25 mg) injection was performed to treat persistent serous retinal detachment at macula causing visual loss. There was a reduction of subretinal fluid and concomitant improvement of BCVA to 20/30 within 1 week after intravitreal bevacizumab injection. The BCVA recovered to 20/25 in the left eye after 4 weeks, and only a minimal amount of residual fluid remained according to OCT. Complete resolution of subretinal fluid was observed by OCT at the 6-week follow-up examination, and BCVA improved to 20/20. Good visual acuity (20/20) and stable macula were maintained in the left eye at 1 year of follow-up without recurrence of subretinal fluid accumulation or hemorrhage and CNV. There were no ocular or systemic complications associated with intravitreal bevacizumab injection.
  
  
  CONCLUSIONS
  Early intravitreal bevacizumab injection could be an effective treatment option for patients with vision loss associated with traumatic choroidal rupture and subretinal fluid within the posterior pole before development of CNV.
authors.affiliation: *MD Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Gangnam-gu, Seoul, Korea (MK, JHK, YS); and Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea (HJK, SCL).
authors.forename: Min
authors.initials: M
authors.lastname: Kim
authors.forename: Jin Hyung
authors.initials: JH
authors.lastname: Kim
authors.forename: Yuri
authors.initials: Y
authors.lastname: Seo
authors.forename: Hyoung Jun
authors.initials: HJ
authors.lastname: Koh
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Lee
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D002829:Choroid / Q000293:injuries*; D005131:Eye Injuries / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D012163:Retinal Detachment / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012166:Retinal Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D012421:Rupture; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014949:Wounds, Nonpenetrating / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab